(Medtronic Press Release) DUBLIN, March 4, 2021 /PRNewswire(opens new window)/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arno ..read more

BGR.com news: According to a research study recently published in the New England Journal of Medicine, the drug helped people shed an average of 15% of their body weight after 68 weeks ..read more

EurekAlert: The Korea Institute of Science and Technology (KIST) announced that the collaborative research team led by Dr. Kwan Hyi Lee from the Biomaterials Research Center and Professor In Gab Jeong from Asan Medical Center developed a technique for diagnosing prostate cancer from urine within only twenty minutes with almost 100% accuracy ..read more

Agenda................... Your registration includes access to all tracks and sessions. This year's conference agenda also includes a new on-demand library that provides the benefit of material, background and informational sessions that build on each other, in preparation for participation in the actual conference. You will have the convenience to review the sessions provided in the on-demand library, days in advance of the conference, as well as the flexibility to review the on-demand online library in advance of the conference dates ..read more

On Monday (Dec. 14), the agency approved these swine, known as GalSafe pigs, for both human food consumption and potential therapeutic purposes, such as use in xenotransplantation (or transplants of pig tissues to people). It's the first time that a genetically engineered animal has been approved for both food and medical uses, the FDA said ..read more

ASN: Burton D. Rose, MD April 24, 2020 Dr. Burton ("Bud") David Rose, a world-renowned clinician, scientist, and educator, died on April 24, 2020 at the age of 77. Better known as Bud, Dr. Rose was a clinical professor of medicine at Harvard University and the co-founder of UpToDate, a well-known resource that enables practicing clinicians to access the latest expert medical information online ..read more

Interim Additional Guidance for Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed COVID-19 in Outpatient Hemodialysis Facilities. These recommendations should be used with the CDC’s Interim Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under Investigation for COVID-19 in Healthcare Settings. This information is provided to clarify COVID-19 infection prevention and control (IPC) recommendations that are specific to outpatient hemodialysis facilities. This information complements ..read more

For your convenience, Nephrologists Transforming Dialysis Safety (NTDS) has also added a "COVID-19" section to its website. This online resource provides links to updated COVID-19 information from CDC as well as the US Food and Drug Administration, Organ Procurement and Transplantation Organization, World Health Organization, and other key stakeholders. ASN will update its online resources as more information becomes available. Please check periodically for updates to the FAQs and other COVID-19 information ..read more

Becker Hospital Review (Maia Anderson): Akebia believes its drug was denied coverage because CMS officials consider it a mineral, which Medicare typically doesn't cover. Akebia says its treatment is a "synthetic, highly processed compound with a unique structure and novel pharmacologic properties," so it should not be denied, according to STAT ..read more

European Heart Journal (Hermida RC): Conclusion -- Routine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events ..read more